Efecto de la metadoxina en hepatopatías primarias crónicas en caninos:  serie de casos

Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases

Objetivo. Evaluar el efecto de la metadoxina sobre hallazgos paraclínicos, ecográficos e histopatológicos en caninos con hepatopatías primarias a través de una serie de casos. Materiales y métodos. Siete caninos de 2 a 14 años con signos clínicos leves a moderados de hepatopatía primaria, ácidos biliares anormales, valores aumentados de ALT o ALP tres veces sobre el rango superior durante 4 semanas, fueron sometidos a evaluación ecográfica y biopsia hepática Tru-Cut ecoguiada para confirmar la hepatopatía de acuerdo con la clasificación histológica de la WSAVA. Previo a la biopsia, debían tener fibrinógeno >100 mg/dl, plaquetas >100 células x103/µl y tiempo de protrombina <11.5 segundos. Una vez confirmado el diagnóstico histológico, recibieron metadoxina a 17±11.35 mg/kg cada 12 horas durante 4 semanas. El seguimiento clínico, paraclínico, ecográfico e histopatológico se realizó al finalizar este periodo. Resultados. Se detectó una disminución en la presentación de vómito y anorexia (p=0.03), un incremento no significativo de ALT y ALP (p=0.84; p=0.43), una reducción en los ácidos biliares (p=0.4) y ningún cambio en el puntaje ecográfico (p=0.42) o diagnóstico histopatológico (p>0.05). Conclusiones. Pese a las importantes limitaciones, esta serie de casos representa una observación preliminar que sugiere que la metadoxina puede mejorar la presentación clínica de caninos con enfermedad hepática sin modificar las variables paraclínicas, ecográficas o histológicas; se necesitan investigaciones adicionales con un diseño de Ensayo Clínico Aleatorizado para proponer protocolos de indicación de metadoxina en caninos con hepatopatías en la práctica clínica.

1. Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65(3):618–630. http://dx.doi.org/10.1016/j.jhep.2016.04.029
2. Di Miceli M, Gronier B. Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine. Rev Recent Clin Trials. 2018;13(1):114–125. https://doi.org/10.2174/1574887113666180227100217
3. Mirijello A, Addolorato G. Treatment of acute alcohol intoxication: The role of metadoxine. Eur J Intern Med. 2023; 110:128. https://doi.org/10.1016/j.ejim.2023.02.012
4. Shenoy KT, Balakumaran LK, Mathew P, Prasad M, Prabhakar B, Sood A, et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis: A randomized controlled trial. J Clin Exp Hepatol 2014;4(2):94–100. https://doi.org/10.1016/j.jceh.2014.03.041
5. Mirijello A, Sestito L, Antonelli M, Gasbarrini A, Addolorato G. Identification and management of acute alcohol intoxication. Eur J Intern Med 2022; 108:1–8. https://doi.org/10.1016/j.ejim.2022.08.013
6. Gutiérrez-Ruiz MC, Bucio L, Correa A, Souza V, Hernández E, Gómez-Quiroz LE, et al. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol Res. 2001; 44(5):431–436. https://doi.org/10.1006/phrs.2001.0883
7. Mazraati P, Minaiyan M. Hepatoprotective Effect of Metadoxine on Acetaminophen-induced Liver Toxicity in Mice. Adv Biomed Res. 2018; 7(1):67. https://doi.org/10.4103/abr.abr_142_17
8. Yang YM, Kim HE, Ki SH, Kim SG. Metadoxine, an ion-pair of pyridoxine and l-2-pyrrolidone-5-carboxylate, blocks adipocyte differentiation in association with inhibition of the PKA-CREB pathway. Arch Biochem Biophys. 2009; 488(2):91–99. http://dx.doi.org/10.1016/j.abb.2009.07.007
9. Annoni G, Contu L, Tronci MA, Caputo A, Arosio B. Pyridoxol l,2-pyrrolidon-5 carboxylate prevents active fibroplasia in CCl4-treated rats. Pharmacol Res. 1992; 25(1):87–93. https://doi.org/10.1016/S1043-6618(05)80067-2
10. Arosio B, Santambrogio D, Gagliano N, Annoni G. Changes in Expression of the Albumin, Fibronectin and Type I Procollagen Genes in CCl4-Induced Liver Fibrosis: Effect of Pyridoxol L,2-Pyrrolidon-5 Carboxylate. Pharmacol Toxicol. 1993;73(6):301–304. https://doi.org/10.1111/j.1600-0773.1993.tb01355.x
11. Calabrese, V., Calderone, A., Ragusa, N., & Rizza V. Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res 1996; 22(1):17–24.
12. Ki SH, Choi JH, Kim CW, Kim SG. Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity. Chem Biol Interact. 2007; 169(2):80–90. https://doi.org/10.1016/j.cbi.2007.05.008.
13. Caballería J, Parés A, Brú C, Mercader J, Plaza AG, Caballería L, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: Results of a randomized double-blind, placebo-control trial. J Hepatol. 1998; 28(1):54–60. https://doi.org/10.1016/S0168-8278(98)80202-X
14. Shpilenya L, Muzychenko A, Gasbarrini G, Addolarato G. Metadoxine in acute alcohol intoxication: a doble blind. Alcohol Clínical. 2002; 26(3):340–346. https://doi.org/10.1111/j.1530-0277.2002.tb02543.x
15. Fehér J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res. 2003; 31(6):537–551. https://doi.org/10.1177/147323000303100610
16. Díaz Martínez MCLR, Díaz Martínez A, Villamil Salcedo V, Cruz Fuentes C. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res. 2002; 30(1):44–51. https://doi.org/10.1177/147323000203000107
17. Higuera-De la Tijera F, Servín-Caamaño AI, Cruz-Herrera J, Serralde-Zúñiga AE, Abdo-Francis JM, Gutiérrez-Reyes G, et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic Hepatitis. Ann Hepatol. 2014; 13(3):343–352. https://doi.org/10.1016/S1665-2681(19)30863-4
18. Higuera-De La Tijera F, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015; 21(16):4975–4985. https://doi.org/10.3748/wjg.v21.i16.4975
19. Bermúdez Duarte PM, Rivera Rojas JA. Encuesta sobre el uso de la metadoxina en hepatopatías de pequeños animales en Colombia. Rev Med Vet. 2019; 1(37):35–41. https://doi.org/10.19052/mv.vol1.iss37.4
20. Webster CRL, Center SA, Cullen JM, Penninck DG, Richter KP, Twedt DC, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med. 2019; 33(3):1173–200. https://doi.org/10.1111/jvim.15467
21. Feeney DA, Anderson KL, Ziegler LE, Jessen CR, Daubs BM, Hardy RM. Statistical relavance of US criteria in diffuse liver disease in dogs and cats. 2008; 69(2). https://doi.org/10.2460/ajvr.69.2.212
22. Lidbury JA. Getting the Most Out of Liver Biopsy. Vet Clin North Am - Small Anim Pract. 2017; 47(3):569–583. https://doi.org/10.1016/j.cvsm.2016.11.007
23. Rothuizen J, Twedt DC. Liver Biopsy Techniques. Vet Clin North Am - Small Anim Pract. 2009; 39(3):469–480. https://doi.org/10.1016/j.cvsm.2009.02.006
24. Rothuizen J, Desmet VJ, van den Ingh TSGAM, Twedt DC, Bunch SE, Washabau RJ. Sampling and handling of liver tissue. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Elsevier Ltd; 2006. http://dx.doi.org/10.1016/B978-0-7020-2791-8.50006-X
25. Boysen SR, Lisciandro GR. The use of ultrasound for dogs and cats in the emergency room AFAST and TFAST. Vet Clin North Am - Small Anim Pract. 2013; 43(4):773–797. https://doi.org/10.1016/j.cvsm.2013.03.011
26. Bermúdez P, Rivera A. Evaluación para Clínica, Ecográfica e Hitológica de caninos con Hepatopatías no neoplásicas tratados con Metadoxina. Maestría en Ciencias Veterinarias. Universidad de la Salle: Colombia; 2018. https://ciencia.lasalle.edu.co/maest_ciencias_veterinarias/79
27. van den Ingh TSGAM, Van Winkle T, Cullen JM, Charles JA, Desmet VJ. Morphological classification of parenchymal disorders of the canine and feline liver: 2. Hepatocellular death, hepatitis and cirrhosis. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Elsevier Ltd; 2006. http://dx.doi.org/10.1016/B978-0-7020-2791-8.50011-3
28. Van Winkle T, Cullen JM, van den Ingh TSGAM, Charles JA, Desmet VJ. Morphological classification of parenchymal disorders of the canine and feline liver: 3. Hepatic abcesses and granulomas, hepatic metabolic storage disorders and miscellaneous conditions. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Elsevier Ltd; 2006. http://dx.doi.org/10.1016/B978-0-7020-2791-8.50012-5
29. Cullen JM, van den Ingh TSGAM, Van Winkle T, Charles JA, Desmet VJ. Morphological classification of parenchymal disorders of the canine and feline liver: 1. Normal histology, reversible hepatocytic injury and hepatic amyloidosis. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. Elsevier Ltd; 2006. http://dx.doi.org/10.1016/B978-0-7020-2791-8.50010-1
30. Caballeria J. Treatment of alcoholic fatty liver: Is the metabolic effect of metadoxine the only reason for improved liver function? J Hepatol. 1999; 30(4):739–740.
31. Webster CRL, Cooper J. Therapeutic Use of Cytoprotective Agents in Canine and Feline Hepatobiliary Disease. Vet Clin North Am - Small Anim Pract. 2009; 39(3):631–652. https://doi.org/10.1016/j.cvsm.2009.02.002
32. Andersen FA. Final safety assessment for PCA and sodium PCA. Int J Toxicol. 1999; 18(SUPPL. 2):25–34. https://doi.org/10.1177/109158189901800206
33. Vanderlinde RE. Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci.1986; 16(2):79–93.
34. Bexfield N. Diagnosing Liver Disease. Clin Br. 2015; 19–22.
35. Mao YM, Zeng M de, Li YM, Wang BY, Shang J, Shi RH, et al. [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study]. Zhonghua Gan Zang Bing Za Zhi. 2009; 17(3):213–216. https://doi.org/10.3760/CMA.J.ISSN.1007-3418.2009.03.013
36. Guerrini I, Gentili C, Nelli G, Guazzelli M. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst Abus Treat Prev Policy. 2006; 1(1):1–5. https://doi.org/10.1186/1747-597X-1-35
37. Leggio L, Kenna G, Ferrulli A, Zywiak W, Caputo F, Swift R, et al. Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. J Clin Psychiatry. 2011; 26:554–549. https://doi.org/10.1002/hup.1244
38. Warren-Smith CMR, Andrew S, Mantis P, Lamb CR. Lack of associations between ultrasonographic appearance of parenchymal lesions of the canine liver and histological diagnosis. J Small Anim Pract. 2012;53(3):168–173. https://doi.org/10.1111/j.1748-5827.2011.01184.x
39. Larson MM. Ultrasound Imaging of the Hepatobiliary System and Pancreas. Vet Clin North Am - Small Anim Pract. 2016; 46(3):453–480. https://doi.org/10.1016/j.cvsm.2015.12.004
40. Kemp SD, Zimmerman KL, Panciera DL, Monroe WE, Leib MS, Lanz OI. A Comparison of Liver Sampling Techniques in Dogs. J Vet Intern Med. 2015; 29(1):51–57. https://doi.org/10.1111/jvim.12508
41. Bedossa P, Dargère D, Paradis V. Sampling Variability of Liver Fibrosis in Chronic Hepatitis C. Hepatology. 2003; 38(6):1449–1457. https://doi.org/10.1016/j.hep.2003.09.022